| Year |
Citation |
Score |
| 2023 |
Burris TP, de Vera IMS, Cote I, Flaveny CA, Wanninayake US, Chatterjee A, Walker JK, Steinauer N, Zhang J, Coons LA, Korach KS, Cain DW, Hollenberg AN, Webb P, Forrest D, et al. . Pharmacological Reviews. PMID 37586884 DOI: 10.1124/pharmrev.121.000436 |
0.759 |
|
| 2023 |
Hampton CS, Sitaula S, Billon C, Haynes K, Avdagic A, Wanninayake U, Adeyemi CM, Chatterjee A, Griffett K, Banerjee S, Burris SL, Schoepke E, Boehm T, Bess A, de Vera IMS, ... Burris TP, et al. Development and pharmacological evaluation of a new chemical series of potent pan-ERR agonists, identification of SLU-PP-915. European Journal of Medicinal Chemistry. 258: 115582. PMID 37421886 DOI: 10.1016/j.ejmech.2023.115582 |
0.78 |
|
| 2023 |
Makhija S, Griffett JD, Veerakanellore GB, Burris TP, Elgendy B, Griffett K. REV-ERB activation as a novel pharmacological approach for treating inflammatory pain. Frontiers in Pharmacology. 14: 1171931. PMID 37153791 DOI: 10.3389/fphar.2023.1171931 |
0.687 |
|
| 2023 |
Griffett K, Burris TP. Development of LXR inverse agonists to treat MAFLD, NASH, and other metabolic diseases. Frontiers in Medicine. 10: 1102469. PMID 36817797 DOI: 10.3389/fmed.2023.1102469 |
0.742 |
|
| 2022 |
Murray MH, Valfort AC, Koelblen T, Ronin C, Ciesielski F, Chatterjee A, Veerakanellore GB, Elgendy B, Walker JK, Hegazy L, Burris TP. Structural basis of synthetic agonist activation of the nuclear receptor REV-ERB. Nature Communications. 13: 7131. PMID 36414641 DOI: 10.1038/s41467-022-34892-4 |
0.384 |
|
| 2022 |
Griffett K, Hayes M, Bedia-Diaz G, Appourchaux K, Sanders R, Boeckman MP, Koelblen T, Zhang J, Schulman IG, Elgendy B, Burris TP. Antihyperlipidemic Activity of Gut-Restricted LXR Inverse Agonists. Acs Chemical Biology. PMID 35417135 DOI: 10.1021/acschembio.2c00057 |
0.732 |
|
| 2022 |
Welch RD, Billon C, Losby M, Bedia-Diaz G, Fang Y, Avdagic A, Elgendy B, Burris TP, Griffett K. Emerging Role of Nuclear Receptors for the Treatment of NAFLD and NASH. Metabolites. 12. PMID 35323681 DOI: 10.3390/metabo12030238 |
0.781 |
|
| 2022 |
Griffett K, Hayes ME, Boeckman MP, Burris TP. The role of REV-ERB in NASH. Acta Pharmacologica Sinica. PMID 35217816 DOI: 10.1038/s41401-022-00883-w |
0.789 |
|
| 2021 |
Elgendy B, Griffett K, Hegazy L, Di Fruscia P, Sample K, Schoepke E, Kamenecka TM, Burris TP. Synthesis and structure activity relationship of the first class of LXR inverse agonists. Bioorganic Chemistry. 119: 105540. PMID 34902646 DOI: 10.1016/j.bioorg.2021.105540 |
0.776 |
|
| 2021 |
Sengupta M, Abuirqeba S, Kameric A, Cecile-Valfort A, Chatterjee A, Griffett K, Burris TP, Flaveny CA. A two-hit model of alcoholic liver disease that exhibits rapid, severe fibrosis. Plos One. 16: e0249316. PMID 33770118 DOI: 10.1371/journal.pone.0249316 |
0.694 |
|
| 2020 |
Kuehm LM, Khojandi N, Piening A, Klevorn LE, Geraud SC, McLaughlin NR, Griffett K, Burris TP, Pyles KD, Nelson AM, Preuss ML, Bockerstett KA, Donlin MJ, McCommis KS, DiPaolo RJ, et al. Fructose promotes cytoprotection in melanoma tumors and resistance to immunotherapy. Cancer Immunology Research. PMID 33023966 DOI: 10.1158/2326-6066.CIR-20-0396 |
0.689 |
|
| 2020 |
Griffett K, Bedia-Diaz G, Elgendy B, Burris TP. REV-ERB agonism improves liver pathology in a mouse model of NASH. Plos One. 15: e0236000. PMID 33002003 DOI: 10.1371/journal.pone.0236000 |
0.731 |
|
| 2020 |
Schoepke E, Billon C, Haynes KM, Avdagic A, Sitaula S, Sanders R, Adeyemi CM, Walker JK, Burris TP. A Selective ERRα/γ Inverse Agonist, SLU-PP-1072, Inhibits the Warburg Effect and Induces Apoptosis in Prostate Cancer Cells. Acs Chemical Biology. PMID 32897058 DOI: 10.1021/Acschembio.0C00670 |
0.444 |
|
| 2020 |
Dvorak Z, Klapholz M, Burris TP, Willing BP, Gioiello A, Pellicciari R, Galli F, March J, Sartor RB, Kim C, Levy M, Mani S, O'Keefe SJ. . Molecular Pharmacology. PMID 32764096 DOI: 10.1124/Molpharm.120.000035 |
0.375 |
|
| 2020 |
Griffett K, Bedia-Diaz G, Hegazy L, de Vera IMS, Wanninayake US, Billon C, Koelblen T, Wilhelm ML, Burris TP. The Orphan Nuclear Receptor TLX Is a Receptor for Synthetic and Natural Retinoids. Cell Chemical Biology. PMID 32763139 DOI: 10.1016/J.Chembiol.2020.07.013 |
0.788 |
|
| 2020 |
Shahien M, Elagawany M, Sitaula S, Goher SS, Burris SL, Sanders R, Avdagic A, Billon C, Hegazy L, Burris TP, Elgendy B. Modulation of estrogen-related receptors subtype selectivity: Conversion of an ERRβ/γ selective agonist to ERRα/β/γ pan agonists. Bioorganic Chemistry. 102: 104079. PMID 32683181 DOI: 10.1016/J.Bioorg.2020.104079 |
0.465 |
|
| 2019 |
Wang Q, Robinette ML, Billon C, Collins PL, Bando JK, Fachi JL, Sécca C, Porter SI, Saini A, Gilfillan S, Solt LA, Musiek ES, Oltz EM, Burris TP, Colonna M. Circadian rhythm-dependent and circadian rhythm-independent impacts of the molecular clock on type 3 innate lymphoid cells. Science Immunology. 4. PMID 31586012 DOI: 10.1126/Sciimmunol.Aay7501 |
0.31 |
|
| 2019 |
Chang C, Loo CS, Zhao X, Solt LA, Liang Y, Bapat SP, Cho H, Kamenecka TM, Leblanc M, Atkins AR, Yu RT, Downes M, Burris TP, Evans RM, Zheng Y. The nuclear receptor REV-ERBα modulates Th17 cell-mediated autoimmune disease. Proceedings of the National Academy of Sciences of the United States of America. PMID 31455731 DOI: 10.1073/Pnas.1907563116 |
0.427 |
|
| 2019 |
Kim WS, Shalit ZA, Nguyen SM, Schoepke E, Eastman A, Burris TP, Gaur AB, Micalizio GC. A synthesis strategy for tetracyclic terpenoids leads to agonists of ERβ. Nature Communications. 10: 2448. PMID 31164645 DOI: 10.1038/S41467-019-10415-6 |
0.337 |
|
| 2019 |
Roby DA, Ruiz F, Kermath BA, Voorhees JR, Niehoff M, Zhang J, Morley JE, Musiek ES, Farr SA, Burris TP. Pharmacological activation of the nuclear receptor REV-ERB reverses cognitive deficits and reduces amyloid-β burden in a mouse model of Alzheimer's disease. Plos One. 14: e0215004. PMID 30973894 DOI: 10.1371/Journal.Pone.0215004 |
0.306 |
|
| 2019 |
Griffin P, Dimitry JM, Sheehan PW, Lananna BV, Guo C, Robinette ML, Hayes ME, Cedeño MR, Nadarajah CJ, Ezerskiy LA, Colonna M, Zhang J, Bauer AQ, Burris TP, Musiek ES. Circadian clock protein Rev-erbα regulates neuroinflammation. Proceedings of the National Academy of Sciences of the United States of America. PMID 30792350 DOI: 10.1073/Pnas.1812405116 |
0.348 |
|
| 2018 |
Sengupta M, Griffett K, Flaveny CA, Burris TP. Inhibition of Hepatotoxicity by a LXR Inverse Agonist in a Model of Alcoholic Liver Disease. Acs Pharmacology & Translational Science. 1: 50-60. PMID 31696159 DOI: 10.1021/acsptsci.8b00003 |
0.72 |
|
| 2018 |
Goher SS, Griffett K, Hegazy L, Elagawany M, Arief MMH, Avdagic A, Banerjee S, Burris TP, Elgendy B. Development of novel liver X receptor modulators based on a 1,2,4-triazole scaffold. Bioorganic & Medicinal Chemistry Letters. PMID 30587446 DOI: 10.1016/J.Bmcl.2018.12.025 |
0.749 |
|
| 2018 |
Billon C, Murray MH, Avdagic A, Burris TP. RORγ Regulates the NLRP3 Inflammasome. The Journal of Biological Chemistry. PMID 30455347 DOI: 10.1074/Jbc.Ac118.002127 |
0.342 |
|
| 2018 |
El-Gendy BEM, Goher S, Hegazy L, Arief MMH, Burris TP. Recent Advances in the Medicinal Chemistry of Liver X Receptors. Journal of Medicinal Chemistry. PMID 30004226 DOI: 10.1021/Acs.Jmedchem.8B00045 |
0.512 |
|
| 2018 |
Amador A, Campbell S, Kazantzis M, Lan G, Burris TP, Solt LA. Distinct roles for REV-ERBα and REV-ERBβ in oxidative capacity and mitochondrial biogenesis in skeletal muscle. Plos One. 13: e0196787. PMID 29723273 DOI: 10.1371/Journal.Pone.0196787 |
0.353 |
|
| 2018 |
Das V, Kc R, Li X, Varma D, Qiu S, Kroin JS, Forsyth CB, Keshavarzian A, van Wijnen AJ, Park TJ, Stein GS, O-Sullivan I, Burris TP, Im HJ. Pharmacological targeting of the mammalian clock reveals a novel analgesic for osteoarthritis-induced pain. Gene. PMID 29474860 DOI: 10.1016/J.Gene.2018.02.048 |
0.313 |
|
| 2018 |
Das V, Kc R, Li X, Varma D, Qiu S, Kroin JS, Forsyth CB, Keshavarzian A, van Wijnen AJ, Park TJ, Stein GS, O-Sullivan I, Burris TP, Im H. Corrigendum to “Blockade of vascular endothelial growth factor receptor-1 (Flt-1), reveals a novel analgesic for osteoarthritis-induced joint pain” [Gene Rep. 11 (2018) 94–100] Gene Reports. 13: 234. DOI: 10.1016/J.Genrep.2018.05.010 |
0.321 |
|
| 2017 |
Pourcet B, Zecchin M, Ferri L, Beauchamp J, Sitaula S, Billon C, Delhaye S, Vanhoutte J, Mayeuf-Louchart A, Thorel Q, Haas J, Eeckhoute J, Dombrowicz D, Duhem C, Boulinguiez A, ... ... Burris T, et al. Nuclear Receptor Subfamily 1 Group D Member 1 Regulates Circadian Activity Of NLRP3 Inflammasome to Reduce the Severity of Fulminant Hepatitis in Mice. Gastroenterology. PMID 29277561 DOI: 10.1053/J.Gastro.2017.12.019 |
0.399 |
|
| 2017 |
Zhang L, Zhang R, Tien CL, Chan RE, Sugi K, Fu C, Griffin AC, Shen Y, Burris TP, Liao X, Jain MK. REV-ERBα ameliorates heart failure through transcription repression. Jci Insight. 2. PMID 28878135 DOI: 10.1172/Jci.Insight.95177 |
0.313 |
|
| 2017 |
Billon C, Sitaula S, Burris TP. Metabolic Characterization of a Novel RORα Knockout Mouse Model without Ataxia. Frontiers in Endocrinology. 8: 141. PMID 28744254 DOI: 10.3389/Fendo.2017.00141 |
0.392 |
|
| 2017 |
Alibhai FJ, LaMarre J, Reitz CJ, Tsimakouridze EV, Kroetsch JT, Bolz SS, Shulman A, Steinberg S, Burris TP, Oudit GY, Martino TA. Disrupting the Key Circadian Regulator CLOCK leads to Age-Dependent Cardiovascular Disease. Journal of Molecular and Cellular Cardiology. PMID 28223222 DOI: 10.1016/J.Yjmcc.2017.01.008 |
0.3 |
|
| 2017 |
Sitaula S, Zhang J, Ruiz F, Burris TP. Rev-erb Regulation of Cholesterologenesis. Biochemical Pharmacology. PMID 28213272 DOI: 10.1016/J.Bcp.2017.02.006 |
0.397 |
|
| 2016 |
Burris TP. Nuclear receptors: PPARα ligands make memories. Nature Chemical Biology. 12: 993-994. PMID 27846207 DOI: 10.1038/Nchembio.2241 |
0.391 |
|
| 2016 |
Griffett K, Burris TP. Promiscuous activity of the LXR antagonist GSK2033 in a mouse model of fatty liver disease. Biochemical and Biophysical Research Communications. PMID 27680310 DOI: 10.1016/J.Bbrc.2016.09.036 |
0.785 |
|
| 2016 |
Amador A, Huitron-Resendiz S, Roberts AJ, Kamenecka TM, Solt LA, Burris TP. Pharmacological Targeting the REV-ERBs in Sleep/Wake Regulation. Plos One. 11: e0162452. PMID 27603791 DOI: 10.1371/Journal.Pone.0162452 |
0.334 |
|
| 2016 |
Amador A, Wang Y, Banerjee S, Kameneka TM, Solt LA, Burris TP. Pharmacological and Genetic Modulation of REV-ERB Activity and Expression Affects Orexigenic Gene Expression. Plos One. 11: e0151014. PMID 26963516 DOI: 10.1371/Journal.Pone.0151014 |
0.394 |
|
| 2015 |
Wang Y, Billon C, Walker JK, Burris TP. Therapeutic Effect of a Synthetic RORα/γ Agonist in an Animal Model of Autism. Acs Chemical Neuroscience. PMID 26625251 DOI: 10.1021/Acschemneuro.5B00159 |
0.405 |
|
| 2015 |
Butler AA, Burris TP. Segregation of Clock and Non-Clock Regulatory Functions of REV-ERB. Cell Metabolism. 22: 197-8. PMID 26244927 DOI: 10.1016/J.Cmet.2015.07.014 |
0.318 |
|
| 2015 |
Flaveny CA, Griffett K, El-Gendy Bel-D, Kazantzis M, Sengupta M, Amelio AL, Chatterjee A, Walker J, Solt LA, Kamenecka TM, Burris TP. Broad Anti-tumor Activity of a Small Molecule that Selectively Targets the Warburg Effect and Lipogenesis. Cancer Cell. 28: 42-56. PMID 26120082 DOI: 10.1016/J.Ccell.2015.05.007 |
0.775 |
|
| 2015 |
Wang Y, Kojetin D, Burris TP. Anti-proliferative actions of a synthetic REV-ERBα/β agonist in breast cancer cells. Biochemical Pharmacology. 96: 315-22. PMID 26074263 DOI: 10.1016/J.Bcp.2015.06.010 |
0.665 |
|
| 2015 |
Griffett K, Welch RD, Flaveny CA, Kolar GR, Neuschwander-Tetri BA, Burris TP. The LXR inverse agonist SR9238 suppresses fibrosis in a model of non-alcoholic steatohepatitis. Molecular Metabolism. 4: 353-7. PMID 25830098 DOI: 10.1016/J.Molmet.2015.01.009 |
0.724 |
|
| 2015 |
Sitaula S, Billon C, Kamenecka TM, Solt LA, Burris TP. Suppression of atherosclerosis by synthetic REV-ERB agonist. Biochemical and Biophysical Research Communications. 460: 566-71. PMID 25800870 DOI: 10.1016/J.Bbrc.2015.03.070 |
0.409 |
|
| 2015 |
Burkholder TP, Cunningham BE, Clayton JR, Lander PA, Brown ML, Doti RA, Durst GL, Montrose-Rafizadeh C, King C, Osborne HE, Amos RM, Zink RW, Stramm LE, Burris TP, Cardona G, et al. Design and synthesis of a novel series of [1-(4-hydroxy-benzyl)-1H-indol-5-yloxy]-acetic acid compounds as potent, selective, thyroid hormone receptor β agonists. Bioorganic & Medicinal Chemistry Letters. 25: 1377-80. PMID 25752984 DOI: 10.1016/J.Bmcl.2015.02.062 |
0.377 |
|
| 2015 |
Solt LA, Banerjee S, Campbell S, Kamenecka TM, Burris TP. ROR inverse agonist suppresses insulitis and prevents hyperglycemia in a mouse model of type 1 diabetes. Endocrinology. 156: 869-81. PMID 25560829 DOI: 10.1210/En.2014-1677 |
0.335 |
|
| 2015 |
Guo C, Li Y, Gow CH, Wong M, Zha J, Yan C, Liu H, Wang Y, Burris TP, Zhang J. The optimal corepressor function of nuclear receptor corepressor (NCoR) for peroxisome proliferator-activated receptor γ requires G protein pathway suppressor 2. The Journal of Biological Chemistry. 290: 3666-79. PMID 25519902 DOI: 10.1074/Jbc.M114.598797 |
0.49 |
|
| 2014 |
Banerjee S, Wang Y, Solt LA, Griffett K, Kazantzis M, Amador A, El-Gendy BM, Huitron-Resendiz S, Roberts AJ, Shin Y, Kamenecka TM, Burris TP. Pharmacological targeting of the mammalian clock regulates sleep architecture and emotional behaviour. Nature Communications. 5: 5759. PMID 25536025 DOI: 10.1038/Ncomms6759 |
0.736 |
|
| 2014 |
Vieira E, Burris TP, Quesada I. Clock genes, pancreatic function, and diabetes. Trends in Molecular Medicine. 20: 685-93. PMID 25457619 DOI: 10.1016/J.Molmed.2014.10.007 |
0.303 |
|
| 2014 |
Christopoulos A, Changeux JP, Catterall WA, Fabbro D, Burris TP, Cidlowski JA, Olsen RW, Peters JA, Neubig RR, Pin JP, Sexton PM, Kenakin TP, Ehlert FJ, Spedding M, Langmead CJ. International Union of Basic and Clinical Pharmacology. XC. multisite pharmacology: recommendations for the nomenclature of receptor allosterism and allosteric ligands. Pharmacological Reviews. 66: 918-47. PMID 25026896 DOI: 10.1124/Pr.114.008862 |
0.488 |
|
| 2014 |
Matta-Camacho E, Banerjee S, Hughes TS, Solt LA, Wang Y, Burris TP, Kojetin DJ. Structure of REV-ERBβ ligand-binding domain bound to a porphyrin antagonist. The Journal of Biological Chemistry. 289: 20054-66. PMID 24872411 DOI: 10.1074/Jbc.M113.545111 |
0.7 |
|
| 2014 |
Hughes TS, Giri PK, de Vera IM, Marciano DP, Kuruvilla DS, Shin Y, Blayo AL, Kamenecka TM, Burris TP, Griffin PR, Kojetin DJ. An alternate binding site for PPARγ ligands. Nature Communications. 5: 3571. PMID 24705063 DOI: 10.1038/Ncomms4571 |
0.68 |
|
| 2014 |
Kojetin DJ, Burris TP. REV-ERB and ROR nuclear receptors as drug targets. Nature Reviews. Drug Discovery. 13: 197-216. PMID 24577401 DOI: 10.1038/Nrd4100 |
0.734 |
|
| 2014 |
Flaveny CA, Solt LA, Kojetin DJ, Burris TP. Biased Signaling and Conformational Dynamics in Nuclear Hormone Receptors Biased Signaling in Physiology, Pharmacology and Therapeutics. 103-135. DOI: 10.1016/B978-0-12-411460-9.00004-5 |
0.632 |
|
| 2013 |
Griffett K, Burris TP. The mammalian clock and chronopharmacology. Bioorganic & Medicinal Chemistry Letters. 23: 1929-34. PMID 23481644 DOI: 10.1016/J.Bmcl.2013.02.015 |
0.716 |
|
| 2013 |
Burris TP, Solt LA, Wang Y, Crumbley C, Banerjee S, Griffett K, Lundasen T, Hughes T, Kojetin DJ. Nuclear receptors and their selective pharmacologic modulators. Pharmacological Reviews. 65: 710-78. PMID 23457206 DOI: 10.1124/Pr.112.006833 |
0.813 |
|
| 2013 |
Griffett K, Solt LA, El-Gendy Bel-D, Kamenecka TM, Burris TP. A liver-selective LXR inverse agonist that suppresses hepatic steatosis. Acs Chemical Biology. 8: 559-67. PMID 23237488 DOI: 10.1021/Cb300541G |
0.734 |
|
| 2013 |
Kojetin DJ, Burris TP. Small molecule modulation of nuclear receptor conformational dynamics: implications for function and drug discovery. Molecular Pharmacology. 83: 1-8. PMID 22869589 DOI: 10.1124/Mol.112.079285 |
0.733 |
|
| 2012 |
Solt LA, Kamenecka TM, Burris TP. LXR-mediated inhibition of CD4+ T helper cells. Plos One. 7: e46615. PMID 23029557 DOI: 10.1371/Journal.Pone.0046615 |
0.308 |
|
| 2012 |
Solt LA, Burris TP. Action of RORs and their ligands in (patho)physiology. Trends in Endocrinology and Metabolism: Tem. 23: 619-27. PMID 22789990 DOI: 10.1016/J.Tem.2012.05.012 |
0.485 |
|
| 2012 |
Solt LA, Kumar N, He Y, Kamenecka TM, Griffin PR, Burris TP. Identification of a selective RORγ ligand that suppresses T(H)17 cells and stimulates T regulatory cells. Acs Chemical Biology. 7: 1515-9. PMID 22769242 DOI: 10.1021/Cb3002649 |
0.371 |
|
| 2012 |
Shin Y, Noel R, Banerjee S, Kojetin D, Song X, He Y, Lin L, Cameron MD, Burris TP, Kamenecka TM. Small molecule tertiary amines as agonists of the nuclear hormone receptor Rev-erbα. Bioorganic & Medicinal Chemistry Letters. 22: 4413-7. PMID 22633688 DOI: 10.1016/J.Bmcl.2012.04.126 |
0.68 |
|
| 2012 |
Noel R, Song X, Shin Y, Banerjee S, Kojetin D, Lin L, Ruiz CH, Cameron MD, Burris TP, Kamenecka TM. Synthesis and SAR of tetrahydroisoquinolines as Rev-erbα agonists. Bioorganic & Medicinal Chemistry Letters. 22: 3739-42. PMID 22560469 DOI: 10.1016/J.Bmcl.2012.04.023 |
0.62 |
|
| 2012 |
Wang Y, Solt LA, Kojetin DJ, Burris TP. Regulation of p53 stability and apoptosis by a ROR agonist. Plos One. 7: e34921. PMID 22509368 DOI: 10.1371/Journal.Pone.0034921 |
0.653 |
|
| 2012 |
Crumbley C, Wang Y, Banerjee S, Burris TP. Regulation of expression of citrate synthase by the retinoic acid receptor-related orphan receptor α (RORα). Plos One. 7: e33804. PMID 22485150 DOI: 10.1371/Journal.Pone.0033804 |
0.818 |
|
| 2012 |
Solt LA, Wang Y, Banerjee S, Hughes T, Kojetin DJ, Lundasen T, Shin Y, Liu J, Cameron MD, Noel R, Yoo SH, Takahashi JS, Butler AA, Kamenecka TM, Burris TP. Regulation of circadian behaviour and metabolism by synthetic REV-ERB agonists. Nature. 485: 62-8. PMID 22460951 DOI: 10.1038/Nature11030 |
0.689 |
|
| 2012 |
Kumar N, Lyda B, Chang MR, Lauer JL, Solt LA, Burris TP, Kamenecka TM, Griffin PR. Identification of SR2211: a potent synthetic RORγ-selective modulator. Acs Chemical Biology. 7: 672-7. PMID 22292739 DOI: 10.1021/Cb200496Y |
0.461 |
|
| 2012 |
Burris TP, Busby SA, Griffin PR. Targeting orphan nuclear receptors for treatment of metabolic diseases and autoimmunity. Chemistry & Biology. 19: 51-9. PMID 22284354 DOI: 10.1016/J.Chembiol.2011.12.011 |
0.521 |
|
| 2012 |
Hughes TS, Chalmers MJ, Novick S, Kuruvilla DS, Chang MR, Kamenecka TM, Rance M, Johnson BA, Burris TP, Griffin PR, Kojetin DJ. Ligand and receptor dynamics contribute to the mechanism of graded PPARγ agonism. Structure (London, England : 1993). 20: 139-50. PMID 22244763 DOI: 10.1016/J.Str.2011.10.018 |
0.758 |
|
| 2012 |
Doerdelmann T, Kojetin DJ, Baird-Titus JM, Solt LA, Burris TP, Rance M. Structural and biophysical insights into the ligand-free Pitx2 homeodomain and a ring dermoid of the cornea inducing homeodomain mutant. Biochemistry. 51: 665-76. PMID 22224469 DOI: 10.1021/Bi201639X |
0.706 |
|
| 2011 |
Begriche K, Levasseur PR, Zhang J, Rossi J, Skorupa D, Solt LA, Young B, Burris TP, Marks DL, Mynatt RL, Butler AA. Genetic dissection of the functions of the melanocortin-3 receptor, a seven-transmembrane G-protein-coupled receptor, suggests roles for central and peripheral receptors in energy homeostasis. The Journal of Biological Chemistry. 286: 40771-81. PMID 21984834 DOI: 10.1074/Jbc.M111.278374 |
0.394 |
|
| 2011 |
Solt LA, Kojetin DJ, Burris TP. The REV-ERBs and RORs: molecular links between circadian rhythms and lipid homeostasis. Future Medicinal Chemistry. 3: 623-38. PMID 21526899 DOI: 10.4155/Fmc.11.9 |
0.722 |
|
| 2011 |
Solt LA, Kumar N, Nuhant P, Wang Y, Lauer JL, Liu J, Istrate MA, Kamenecka TM, Roush WR, Vidovi? D, Schürer SC, Xu J, Wagoner G, Drew PD, Griffin PR, ... Burris TP, et al. Suppression of TH17 differentiation and autoimmunity by a synthetic ROR ligand. Nature. 472: 491-4. PMID 21499262 DOI: 10.1038/Nature10075 |
0.405 |
|
| 2011 |
Crumbley C, Burris TP. Direct regulation of CLOCK expression by REV-ERB. Plos One. 6: e17290. PMID 21479263 DOI: 10.1371/Journal.Pone.0017290 |
0.791 |
|
| 2011 |
Zhang J, Chalmers MJ, Stayrook KR, Burris LL, Wang Y, Busby SA, Pascal BD, Garcia-Ordonez RD, Bruning JB, Istrate MA, Kojetin DJ, Dodge JA, Burris TP, Griffin PR. DNA binding alters coactivator interaction surfaces of the intact VDR-RXR complex. Nature Structural & Molecular Biology. 18: 556-63. PMID 21478866 DOI: 10.1038/Nsmb.2046 |
0.709 |
|
| 2011 |
Busby SA, Kumar N, Kuruvilla DS, Istrate MA, Conkright JJ, Wang Y, Kamenecka TM, Cameron MD, Roush WR, Burris TP, Griffin PR. Identification of a novel non-retinoid pan inverse agonist of the retinoic acid receptors. Acs Chemical Biology. 6: 618-27. PMID 21381756 DOI: 10.1021/Cb100396S |
0.504 |
|
| 2011 |
Kojetin DJ, Burris TP. A role for rev-erbα ligands in regulation of adipogenesis. Current Pharmaceutical Design. 17: 320-4. PMID 21375499 DOI: 10.2174/138161211795164211 |
0.72 |
|
| 2011 |
Shen Q, Bai Y, Chang KC, Wang Y, Burris TP, Freedman LP, Thompson CC, Nagpal S. Liver X receptor-retinoid X receptor (LXR-RXR) heterodimer cistrome reveals coordination of LXR and AP1 signaling in keratinocytes. The Journal of Biological Chemistry. 286: 14554-63. PMID 21349840 DOI: 10.1074/Jbc.M110.165704 |
0.409 |
|
| 2011 |
Kumar N, Kojetin DJ, Solt LA, Kumar KG, Nuhant P, Duckett DR, Cameron MD, Butler AA, Roush WR, Griffin PR, Burris TP. Identification of SR3335 (ML-176): a synthetic RORα selective inverse agonist. Acs Chemical Biology. 6: 218-22. PMID 21090593 DOI: 10.1021/Cb1002762 |
0.722 |
|
| 2011 |
Kojetin D, Wang Y, Kamenecka TM, Burris TP. Identification of SR8278, a synthetic antagonist of the nuclear heme receptor REV-ERB. Acs Chemical Biology. 6: 131-4. PMID 21043485 DOI: 10.1021/Cb1002575 |
0.737 |
|
| 2011 |
Wang Y, Kamenecka T, Kojetin D, Burris TP. Abstract 1357: Inhibition of breast cancer cell growth by a synthetic ligand targeting the nuclear receptor, REV-ERB (NR1D1 and NR1D2) Cancer Research. 71: 1357-1357. DOI: 10.1158/1538-7445.Am2011-1357 |
0.621 |
|
| 2010 |
Zhang J, Chalmers MJ, Stayrook KR, Burris LL, Garcia-Ordonez RD, Pascal BD, Burris TP, Dodge JA, Griffin PR. Hydrogen/deuterium exchange reveals distinct agonist/partial agonist receptor dynamics within vitamin D receptor/retinoid X receptor heterodimer. Structure (London, England : 1993). 18: 1332-41. PMID 20947021 DOI: 10.1016/J.Str.2010.07.007 |
0.481 |
|
| 2010 |
Crumbley C, Wang Y, Kojetin DJ, Burris TP. Characterization of the core mammalian clock component, NPAS2, as a REV-ERBalpha/RORalpha target gene. The Journal of Biological Chemistry. 285: 35386-92. PMID 20817722 DOI: 10.1074/Jbc.M110.129288 |
0.804 |
|
| 2010 |
Wang Y, Kumar N, Nuhant P, Cameron MD, Istrate MA, Roush WR, Griffin PR, Burris TP. Identification of SR1078, a synthetic agonist for the orphan nuclear receptors RORα and RORγ. Acs Chemical Biology. 5: 1029-34. PMID 20735016 DOI: 10.1021/Cb100223D |
0.535 |
|
| 2010 |
Solt LA, Griffin PR, Burris TP. Ligand regulation of retinoic acid receptor-related orphan receptors: implications for development of novel therapeutics. Current Opinion in Lipidology. 21: 204-11. PMID 20463469 DOI: 10.1097/Mol.0B013E328338Ca18 |
0.493 |
|
| 2010 |
Kumar N, Solt LA, Wang Y, Rogers PM, Bhattacharyya G, Kamenecka TM, Stayrook KR, Crumbley C, Floyd ZE, Gimble JM, Griffin PR, Burris TP. Regulation of adipogenesis by natural and synthetic REV-ERB ligands. Endocrinology. 151: 3015-25. PMID 20427485 DOI: 10.1210/En.2009-0800 |
0.827 |
|
| 2010 |
Wang Y, Solt LA, Burris TP. Regulation of FGF21 expression and secretion by retinoic acid receptor-related orphan receptor alpha. The Journal of Biological Chemistry. 285: 15668-73. PMID 20332535 DOI: 10.1074/Jbc.M110.102160 |
0.464 |
|
| 2010 |
Wang Y, Kumar N, Crumbley C, Griffin PR, Burris TP. A second class of nuclear receptors for oxysterols: Regulation of RORalpha and RORgamma activity by 24S-hydroxycholesterol (cerebrosterol). Biochimica Et Biophysica Acta. 1801: 917-23. PMID 20211758 DOI: 10.1016/J.Bbalip.2010.02.012 |
0.839 |
|
| 2010 |
Wang Y, Kumar N, Solt LA, Richardson TI, Helvering LM, Crumbley C, Garcia-Ordonez RD, Stayrook KR, Zhang X, Novick S, Chalmers MJ, Griffin PR, Burris TP. Modulation of retinoic acid receptor-related orphan receptor alpha and gamma activity by 7-oxygenated sterol ligands. The Journal of Biological Chemistry. 285: 5013-25. PMID 19965867 DOI: 10.1074/Jbc.M109.080614 |
0.813 |
|
| 2010 |
Kumar N, Solt LA, Conkright JJ, Wang Y, Istrate MA, Busby SA, Garcia-Ordonez RD, Burris TP, Griffin PR. The benzenesulfoamide T0901317 [N-(2,2,2-trifluoroethyl)-N-[4-[2,2,2-trifluoro-1-hydroxy-1-(trifluoromethyl)ethyl]phenyl]-benzenesulfonamide] is a novel retinoic acid receptor-related orphan receptor-alpha/gamma inverse agonist. Molecular Pharmacology. 77: 228-36. PMID 19887649 DOI: 10.1124/Mol.109.060905 |
0.498 |
|
| 2009 |
Dai SY, Burris TP, Dodge JA, Montrose-Rafizadeh C, Wang Y, Pascal BD, Chalmers MJ, Griffin PR. Unique ligand binding patterns between estrogen receptor alpha and beta revealed by hydrogen-deuterium exchange. Biochemistry. 48: 9668-76. PMID 19739677 DOI: 10.1021/Bi901149T |
0.393 |
|
| 2008 |
Chandra V, Huang P, Hamuro Y, Raghuram S, Wang Y, Burris TP, Rastinejad F. Structure of the intact PPAR-gamma-RXR- nuclear receptor complex on DNA. Nature. 456: 350-6. PMID 19043829 DOI: 10.1038/Nature07413 |
0.422 |
|
| 2008 |
Kumar KG, Trevaskis JL, Lam DD, Sutton GM, Koza RA, Chouljenko VN, Kousoulas KG, Rogers PM, Kesterson RA, Thearle M, Ferrante AW, Mynatt RL, Burris TP, Dong JZ, Halem HA, et al. Identification of adropin as a secreted factor linking dietary macronutrient intake with energy homeostasis and lipid metabolism. Cell Metabolism. 8: 468-81. PMID 19041763 DOI: 10.1016/J.Cmet.2008.10.011 |
0.345 |
|
| 2008 |
Wang Y, Rogers PM, Stayrook KR, Su C, Varga G, Shen Q, Nagpal S, Burris TP. The selective Alzheimer's disease indicator-1 gene (Seladin-1/DHCR24) is a liver X receptor target gene Molecular Pharmacology. 74: 1716-1721. PMID 18815215 DOI: 10.1124/Mol.108.048538 |
0.456 |
|
| 2008 |
Kojetin DJ, Burris TP, Jensen EV, Khan SA. Implications of the binding of tamoxifen to the coactivator recognition site of the estrogen receptor. Endocrine-Related Cancer. 15: 851-70. PMID 18755852 DOI: 10.1677/Erc-07-0281 |
0.704 |
|
| 2008 |
Wang Y, Rogers PM, Su C, Varga G, Stayrook KR, Burris TP. Regulation of cholesterologenesis by the oxysterol receptor, LXRα Journal of Biological Chemistry. 283: 26332-26339. PMID 18676367 DOI: 10.1074/Jbc.M804808200 |
0.44 |
|
| 2008 |
Dai SY, Chalmers MJ, Bruning J, Bramlett KS, Osborne HE, Montrose-Rafizadeh C, Barr RJ, Wang Y, Wang M, Burris TP, Dodge JA, Griffin PR. Prediction of the tissue-specificity of selective estrogen receptor modulators by using a single biochemical method Proceedings of the National Academy of Sciences of the United States of America. 105: 7171-7176. PMID 18474858 DOI: 10.1073/Pnas.0710802105 |
0.452 |
|
| 2008 |
Rogers PM, Ying L, Burris TP. Relationship between circadian oscillations of Rev-erbalpha expression and intracellular levels of its ligand, heme. Biochemical and Biophysical Research Communications. 368: 955-8. PMID 18280802 DOI: 10.1016/J.Bbrc.2008.02.031 |
0.511 |
|
| 2008 |
Burris TP. Nuclear hormone receptors for heme: REV-ERBalpha and REV-ERBbeta are ligand-regulated components of the mammalian clock. Molecular Endocrinology (Baltimore, Md.). 22: 1509-20. PMID 18218725 DOI: 10.1210/Me.2007-0519 |
0.546 |
|
| 2008 |
Stayrook KR, Rogers PM, Savkur RS, Wang Y, Su C, Varga G, Bu X, Wei T, Nagpal S, Liu XS, Burris TP. Regulation of human 3 alpha-hydroxysteroid dehydrogenase (AKR1C4) expression by the liver X receptor alpha. Molecular Pharmacology. 73: 607-12. PMID 18024509 DOI: 10.1124/Mol.107.039099 |
0.477 |
|
| 2007 |
Raghuram S, Stayrook KR, Huang P, Rogers PM, Nosie AK, McClure DB, Burris LL, Khorasanizadeh S, Burris TP, Rastinejad F. Identification of heme as the ligand for the orphan nuclear receptors REV-ERBalpha and REV-ERBbeta. Nature Structural & Molecular Biology. 14: 1207-13. PMID 18037887 DOI: 10.1038/Nsmb1344 |
0.515 |
|
| 2007 |
Kremoser C, Albers M, Burris TP, Deuschle U, Koegl M. Panning for SNuRMs: using cofactor profiling for the rational discovery of selective nuclear receptor modulators. Drug Discovery Today. 12: 860-9. PMID 17933688 DOI: 10.1016/J.Drudis.2007.07.025 |
0.449 |
|
| 2007 |
Chintalacharuvu SR, Sandusky GE, Burris TP, Burmer GC, Nagpal S. Liver X receptor is a therapeutic target in collagen-induced arthritis. Arthritis and Rheumatism. 56: 1365-7. PMID 17393442 DOI: 10.1002/Art.22528 |
0.397 |
|
| 2006 |
Wang Y, Chirgadze NY, Briggs SL, Khan S, Jensen EV, Burris TP. A second binding site for hydroxytamoxifen within the coactivator-binding groove of estrogen receptor beta. Proceedings of the National Academy of Sciences of the United States of America. 103: 9908-11. PMID 16782818 DOI: 10.1073/Pnas.0510596103 |
0.386 |
|
| 2006 |
Ma Y, Khalifa B, Yee YK, Lu J, Memezawa A, Savkur RS, Yamamoto Y, Chintalacharuvu SR, Yamaoka K, Stayrook KR, Bramlett KS, Zeng QQ, Chandrasekhar S, Yu XP, Linebarger JH, ... ... Burris TP, et al. Identification and characterization of noncalcemic, tissue-selective, nonsecosteroidal vitamin D receptor modulators. The Journal of Clinical Investigation. 116: 892-904. PMID 16528410 DOI: 10.1172/Jci25901 |
0.409 |
|
| 2006 |
Wallace OB, Lauwers KS, Dodge JA, May SA, Calvin JR, Hinklin R, Bryant HU, Shetler PK, Adrian MD, Geiser AG, Sato M, Burris TP. A selective estrogen receptor modulator for the treatment of hot flushes Journal of Medicinal Chemistry. 49: 843-846. PMID 16451049 DOI: 10.1021/Jm0509795 |
0.379 |
|
| 2006 |
Schmidt RJ, Ficorilli JV, Zhang Y, Bramlett KS, Beyer TP, Borchert K, Dowless MS, Houck KA, Burris TP, Eacho PI, Liang G, Guo LW, Wilson WK, Michael LF, Cao G. A 15-ketosterol is a liver X receptor ligand that suppresses sterol-responsive element binding protein-2 activity. Journal of Lipid Research. 47: 1037-44. PMID 16415294 DOI: 10.1194/Jlr.M500526-Jlr200 |
0.448 |
|
| 2005 |
Galande AK, Bramlett KS, Trent JO, Burris TP, Wittliff JL, Spatola AF. Potent inhibitors of LXXLL-based protein-protein interactions. Chembiochem : a European Journal of Chemical Biology. 6: 1991-8. PMID 16222726 DOI: 10.1002/Cbic.200500083 |
0.313 |
|
| 2005 |
Michael LF, Schkeryantz JM, Burris TP. The pharmacology of LXR. Mini Reviews in Medicinal Chemistry. 5: 729-40. PMID 16101409 DOI: 10.2174/1389557054553767 |
0.533 |
|
| 2005 |
Burris TP, Krishnan V. Estrogen: a mitochondrial energizer that keeps on going. Molecular Pharmacology. 68: 956-8. PMID 16051746 DOI: 10.1124/Mol.105.017335 |
0.346 |
|
| 2005 |
Schoner BE, Bramlett KS, Guo H, Burris TP. Reconstitution of functional nuclear receptor proteins using high pressure refolding. Molecular Genetics and Metabolism. 85: 318-22. PMID 15946878 DOI: 10.1016/J.Ymgme.2005.04.012 |
0.451 |
|
| 2005 |
Savkur RS, Bramlett KS, Stayrook KR, Nagpal S, Burris TP. Coactivation of the human vitamin D receptor by the peroxisome proliferator-activated receptor gamma coactivator-1 alpha. Molecular Pharmacology. 68: 511-7. PMID 15908514 DOI: 10.1124/Mol.105.012708 |
0.369 |
|
| 2005 |
Savkur RS, Bramlett KS, Michael LF, Burris TP. Regulation of pyruvate dehydrogenase kinase expression by the farnesoid X receptor. Biochemical and Biophysical Research Communications. 329: 391-6. PMID 15721319 DOI: 10.1016/J.Bbrc.2005.01.141 |
0.468 |
|
| 2005 |
Burris TP, Montrose C, Houck KA, Osborne HE, Bocchinfuso WP, Yaden BC, Cheng CC, Zink RW, Barr RJ, Hepler CD, Krishnan V, Bullock HA, Burris LL, Galvin RJ, Bramlett K, et al. The hypolipidemic natural product guggulsterone is a promiscuous steroid receptor ligand. Molecular Pharmacology. 67: 948-54. PMID 15602004 DOI: 10.1124/Mol.104.007054 |
0.494 |
|
| 2005 |
Stayrook KR, Bramlett KS, Savkur RS, Ficorilli J, Cook T, Christe ME, Michael LF, Burris TP. Regulation of carbohydrate metabolism by the farnesoid X receptor. Endocrinology. 146: 984-91. PMID 15564327 DOI: 10.1210/En.2004-0965 |
0.511 |
|
| 2005 |
Savkur RS, Thomas JS, Bramlett KS, Gao Y, Michael LF, Burris TP. Ligand-dependent coactivation of the human bile acid receptor FXR by the peroxisome proliferator-activated receptor gamma coactivator-1alpha. The Journal of Pharmacology and Experimental Therapeutics. 312: 170-8. PMID 15329387 DOI: 10.1124/Jpet.104.072124 |
0.457 |
|
| 2004 |
Houck KA, Borchert KM, Hepler CD, Thomas JS, Bramlett KS, Michael LF, Burris TP. T0901317 is a dual LXR/FXR agonist. Molecular Genetics and Metabolism. 83: 184-7. PMID 15464433 DOI: 10.1016/J.Ymgme.2004.07.007 |
0.419 |
|
| 2004 |
Savkur RS, Bramlett KS, Clawson D, Burris TP. Pharmacology of Nuclear Receptor-Coregulator Recognition Vitamins and Hormones. 68: 145-183. PMID 15193454 DOI: 10.1016/S0083-6729(04)68005-8 |
0.475 |
|
| 2004 |
Galande AK, Bramlett KS, Burris TP, Wittliff JL, Spatola AF. Thioether side chain cyclization for helical peptide formation: inhibitors of estrogen receptor-coactivator interactions. The Journal of Peptide Research : Official Journal of the American Peptide Society. 63: 297-302. PMID 15049842 DOI: 10.1111/J.1399-3011.2004.00152.X |
0.315 |
|
| 2004 |
Savkur RS, Burris TP. The coactivator LXXLL nuclear receptor recognition motif. The Journal of Peptide Research : Official Journal of the American Peptide Society. 63: 207-12. PMID 15049832 DOI: 10.1111/J.1399-3011.2004.00126.X |
0.477 |
|
| 2004 |
Rybczynski PJ, Zeck RE, Dudash J, Combs DW, Burris TP, Yang M, Osborne MC, Chen X, Demarest KT. Benzoxazinones as PPARgamma agonists. 2. SAR of the amide substituent and in vivo results in a type 2 diabetes model. Journal of Medicinal Chemistry. 47: 196-209. PMID 14695833 DOI: 10.1021/Jm0301888 |
0.313 |
|
| 2003 |
Savkur RS, Wu Y, Bramlett KS, Wang M, Yao S, Perkins D, Totten M, Searfoss G, Ryan TP, Su EW, Burris TP. Alternative splicing within the ligand binding domain of the human constitutive androstane receptor Molecular Genetics and Metabolism. 80: 216-226. PMID 14567971 DOI: 10.1016/J.Ymgme.2003.08.013 |
0.486 |
|
| 2003 |
Leduc AM, Trent JO, Wittliff JL, Bramlett KS, Briggs SL, Chirgadze NY, Wang Y, Burris TP, Spatola AF. Helix-stabilized cyclic peptides as selective inhibitors of steroid receptor-coactivator interactions. Proceedings of the National Academy of Sciences of the United States of America. 100: 11273-8. PMID 13679575 DOI: 10.1073/Pnas.1934759100 |
0.444 |
|
| 2003 |
Bramlett KS, Burris TP. Target specificity of selective estrogen receptor modulators within human endometrial cancer cells. The Journal of Steroid Biochemistry and Molecular Biology. 86: 27-34. PMID 12943742 DOI: 10.1016/S0960-0760(03)00258-9 |
0.42 |
|
| 2003 |
Wang M, Thomas J, Burris TP, Schkeryantz J, Michael LF. Molecular determinants of LXRalpha agonism. Journal of Molecular Graphics & Modelling. 22: 173-81. PMID 12932788 DOI: 10.1016/S1093-3263(03)00159-1 |
0.438 |
|
| 2003 |
Bettoun DJ, Burris TP, Houck KA, Buck DW, Stayrook KR, Khalifa B, Lu J, Chin WW, Nagpal S. Retinoid X receptor is a nonsilent major contributor to vitamin D receptor-mediated transcriptional activation. Molecular Endocrinology (Baltimore, Md.). 17: 2320-8. PMID 12893883 DOI: 10.1210/Me.2003-0148 |
0.486 |
|
| 2003 |
Bramlett KS, Houck KA, Borchert KM, Dowless MS, Kulanthaivel P, Zhang Y, Beyer TP, Schmidt R, Thomas JS, Michael LF, Barr R, Montrose C, Eacho PI, Cao G, Burris TP. A natural product ligand of the oxysterol receptor, liver X receptor. The Journal of Pharmacology and Experimental Therapeutics. 307: 291-6. PMID 12893846 DOI: 10.1124/Jpet.103.052852 |
0.515 |
|
| 2003 |
Wu Y, Chin WW, Wang Y, Burris TP. Ligand and coactivator identity determines the requirement of the charge clamp for coactivation of the peroxisome proliferator-activated receptor gamma. The Journal of Biological Chemistry. 278: 8637-44. PMID 12502716 DOI: 10.1074/Jbc.M210910200 |
0.459 |
|
| 2003 |
Thomas J, Bramlett KS, Montrose C, Foxworthy P, Eacho PI, McCann D, Cao G, Kiefer A, McCowan J, Yu KL, Grese T, Chin WW, Burris TP, Michael LF. A chemical switch regulates fibrate specificity for peroxisome proliferator-activated receptor alpha (PPARalpha ) versus liver X receptor. The Journal of Biological Chemistry. 278: 2403-10. PMID 12441342 DOI: 10.1074/Jbc.M209629200 |
0.509 |
|
| 2003 |
Cao G, Liang Y, Broderick CL, Oldham BA, Beyer TP, Schmidt RJ, Zhang Y, Stayrook KR, Suen C, Otto KA, Miller AR, Dai J, Foxworthy P, Gao H, Ryan TP, ... ... Burris TP, et al. Antidiabetic action of a liver x receptor agonist mediated by inhibition of hepatic gluconeogenesis. The Journal of Biological Chemistry. 278: 1131-6. PMID 12414791 DOI: 10.1074/Jbc.M210208200 |
0.461 |
|
| 2003 |
Bramlett KS, Burris TP. Effects of selective estrogen receptor modulators (SERMs) on coactivator nuclear receptor (NR) box binding to estrogen receptors. Molecular Genetics and Metabolism. 76: 225-33. PMID 12126937 DOI: 10.1016/S1096-7192(02)00043-4 |
0.435 |
|
| 2002 |
Zhang Y, Beyer TP, Bramlett KS, Yao S, Burris TP, Schmidt RJ, Eacho PI, Cao G. Liver X receptor and retinoic X receptor mediated ABCA1 regulation and cholesterol efflux in macrophage cells-messenger RNA measured by branched DNA technology. Molecular Genetics and Metabolism. 77: 150-8. PMID 12359143 DOI: 10.1016/S1096-7192(02)00111-7 |
0.442 |
|
| 2002 |
Ko L, Cardona GR, Iwasaki T, Bramlett KS, Burris TP, Chin WW. Ser-884 adjacent to the LXXLL motif of coactivator TRBP defines selectivity for ERs and TRs. Molecular Endocrinology (Baltimore, Md.). 16: 128-40. PMID 11773444 DOI: 10.1210/Mend.16.1.0755 |
0.471 |
|
| 2002 |
Wu Y, Delerive P, Chin WW, Burris TP. Requirement of helix 1 and the AF-2 domain of the thyroid hormone receptor for coactivation by PGC-1. The Journal of Biological Chemistry. 277: 8898-905. PMID 11751919 DOI: 10.1074/Jbc.M110761200 |
0.481 |
|
| 2002 |
Delerive P, Wu Y, Burris TP, Chin WW, Suen CS. PGC-1 functions as a transcriptional coactivator for the retinoid X receptors. The Journal of Biological Chemistry. 277: 3913-7. PMID 11714715 DOI: 10.1074/Jbc.M109409200 |
0.459 |
|
| 2001 |
Bramlett KS, Wu Y, Burris TP. Ligands specify coactivator nuclear receptor (NR) box affinity for estrogen receptor subtypes. Molecular Endocrinology (Baltimore, Md.). 15: 909-22. PMID 11376110 DOI: 10.1210/Mend.15.6.0649 |
0.494 |
|
| 2001 |
Bramlett KS, Yao S, Burris TP. Correlation of farnesoid X receptor coactivator recruitment and cholesterol 7alpha-hydroxylase gene repression by bile acids. Molecular Genetics and Metabolism. 71: 609-15. PMID 11136553 DOI: 10.1006/Mgme.2000.3106 |
0.452 |
|
| 2000 |
Gurnell M, Wentworth JM, Agostini M, Adams M, Collingwood TN, Provenzano C, Browne PO, Rajanayagam O, Burris TP, Schwabe JW, Lazar MA, Chatterjee VK. A dominant-negative peroxisome proliferator-activated receptor gamma (PPARgamma) mutant is a constitutive repressor and inhibits PPARgamma-mediated adipogenesis. The Journal of Biological Chemistry. 275: 5754-9. PMID 10681562 DOI: 10.1074/Jbc.275.8.5754 |
0.496 |
|
| 2000 |
Wentworth JM, Burris TP, Chatterjee VK. HIV protease inhibitors block human preadipocyte differentiation, but not via the PPARgamma/RXR heterodimer. The Journal of Endocrinology. 164: R7-R10. PMID 10657860 DOI: 10.1677/Joe.0.164R007 |
0.32 |
|
| 1999 |
Pelton PD, Zhou L, Demarest KT, Burris TP. PPARgamma activation induces the expression of the adipocyte fatty acid binding protein gene in human monocytes. Biochemical and Biophysical Research Communications. 261: 456-8. PMID 10425206 DOI: 10.1006/Bbrc.1999.1071 |
0.453 |
|
| 1999 |
Burris TP, Pelton PD, Zhou L, Osborne MC, Cryan E, Demarest KT. A novel method for analysis of nuclear receptor function at natural promoters: peroxisome proliferator-activated receptor gamma agonist actions on aP2 gene expression detected using branched DNA messenger RNA quantitation. Molecular Endocrinology (Baltimore, Md.). 13: 410-7. PMID 10076998 DOI: 10.1210/Mend.13.3.0246 |
0.425 |
|
| 1998 |
Zhang YH, Guo W, Wagner RL, Huang BL, McCabe L, Vilain E, Burris TP, Anyane-Yeboa K, Burghes AH, Chitayat D, Chudley AE, Genel M, Gertner JM, Klingensmith GJ, Levine SN, et al. DAX1 mutations map to putative structural domains in a deduced three-dimensional model. American Journal of Human Genetics. 62: 855-64. PMID 9529340 DOI: 10.1086/301782 |
0.3 |
|
| 1996 |
Guo W, Burris TP, Zhang YH, Huang BL, Mason J, Copeland KC, Kupfer SR, Pagon RA, McCabe ER. Genomic sequence of the DAX1 gene: an orphan nuclear receptor responsible for X-linked adrenal hypoplasia congenita and hypogonadotropic hypogonadism. The Journal of Clinical Endocrinology and Metabolism. 81: 2481-6. PMID 8675564 DOI: 10.1210/Jcem.81.7.8675564 |
0.388 |
|
| 1996 |
Guo W, Burris TP, McCabe ER. Expression of DAX-1, the gene responsible for X-linked adrenal hypoplasia congenita and hypogonadotropic hypogonadism, in the hypothalamic-pituitary-adrenal/gonadal axis. Biochemical and Molecular Medicine. 56: 8-13. PMID 8593542 DOI: 10.1006/Bmme.1995.1049 |
0.346 |
|
| 1995 |
Baniahmad A, Leng X, Burris TP, Tsai SY, Tsai MJ, O'Malley BW. The tau 4 activation domain of the thyroid hormone receptor is required for release of a putative corepressor(s) necessary for transcriptional silencing. Molecular and Cellular Biology. 15: 76-86. PMID 7799971 DOI: 10.1128/Mcb.15.1.76 |
0.563 |
|
| 1995 |
Burris TP, Guo W, Le T, McCabe ER. Identification of a putative steroidogenic factor-1 response element in the DAX-1 promoter. Biochemical and Biophysical Research Communications. 214: 576-81. PMID 7677767 DOI: 10.1006/Bbrc.1995.2324 |
0.355 |
|
| 1995 |
Burris TP, Nawaz Z, Tsai MJ, O'Malley BW. A nuclear hormone receptor-associated protein that inhibits transactivation by the thyroid hormone and retinoic acid receptors Proceedings of the National Academy of Sciences of the United States of America. 92: 9525-9529. PMID 7568167 DOI: 10.1073/Pnas.92.21.9525 |
0.584 |
|
| 1994 |
Burris TP, Freeman ME. Comparison of the forms of the dopamine D2 receptor expressed in GH4C1 cells. Proceedings of the Society For Experimental Biology and Medicine. Society For Experimental Biology and Medicine (New York, N.Y.). 205: 226-35. PMID 8171043 DOI: 10.3181/00379727-205-43701 |
0.607 |
|
| 1994 |
Nawaz Z, Baniahmad C, Burris TP, O'Malley BW, Stillman DJ, TsaiTsaiTsai MJ. The yeast SIN3 gene product negatively regulates the activity of the human progesterone receptor and positively regulates the activities of GAL4 and the HAP1 activator Mgg Molecular &Amp; General Genetics. 245: 724-733. PMID 7830720 DOI: 10.1007/Bf00297279 |
0.526 |
|
| 1993 |
Burris TP, Freeman ME. Low concentrations of dopamine increase cytosolic calcium in lactotrophs. Endocrinology. 133: 63-8. PMID 8391429 DOI: 10.1210/Endo.133.1.8391429 |
0.548 |
|
| 1993 |
Arey BJ, Burris TP, Basco P, Freeman ME. Infusion of dopamine at low concentrations stimulates the release of prolactin from alpha-methyl-p-tyrosine-treated rats. Proceedings of the Society For Experimental Biology and Medicine. Society For Experimental Biology and Medicine (New York, N.Y.). 203: 60-3. PMID 8097329 DOI: 10.3181/00379727-203-43573 |
0.543 |
|
| 1992 |
Burris TP, Nguyen DN, Smith SG, Freeman ME. The stimulatory and inhibitory effects of dopamine on prolactin secretion involve different G-proteins. Endocrinology. 130: 926-32. PMID 1733734 DOI: 10.1210/Endo.130.2.1733734 |
0.553 |
|
| 1991 |
Kanyicska B, Burris TP, Freeman ME. The effects of endothelins on the secretion of prolactin, luteinizing hormone, and follicle-stimulating hormone are mediated by different guanine nucleotide-binding proteins. Endocrinology. 129: 2607-13. PMID 1935791 DOI: 10.1210/Endo-129-5-2607 |
0.561 |
|
| 1991 |
Burris TP, Kanyicska B, Freeman ME. Inhibition of prolactin secretion by endothelin-3 is pertussis toxin-sensitive. European Journal of Pharmacology. 198: 223-5. PMID 1907563 DOI: 10.1016/0014-2999(91)90627-3 |
0.55 |
|
| 1991 |
Kanyicska B, Burris TP, Freeman ME. Endothelin-3 inhibits prolactin and stimulates LH, FSH and TSH secretion from pituitary cell culture. Biochemical and Biophysical Research Communications. 174: 338-43. PMID 1899191 DOI: 10.1016/0006-291X(91)90525-C |
0.551 |
|
| 1991 |
Burris TP, Stringer LC, Freeman ME. Pharmacologic evidence that a D2 receptor subtype mediates dopaminergic stimulation of prolactin secretion from the anterior pituitary gland. Neuroendocrinology. 54: 175-83. PMID 1685014 DOI: 10.1159/000125866 |
0.584 |
|
| Show low-probability matches. |
